openPR Logo
Press release

Polycythemia Vera Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

09-02-2025 11:46 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Polycythemia Vera Pipeline Outlook 2025: Clinical Trial

DelveInsight's, "Polycythemia Vera Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the Polycythemia Vera pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Polycythemia Vera therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Polycythemia Vera Pipeline. Dive into DelveInsight's comprehensive report today! @ Polycythemia Vera Pipeline Outlook [https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Polycythemia Vera Pipeline Report

* On 28 August 2025, Celgene announced a Phase 3 study designed to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in patients with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) who had previously been treated with ruxolitinib. The primary objective of the study is to assess the proportion of patients achieving at least a 35% reduction in spleen volume in both the fedratinib and BAT treatment arms.
* On 24 August 2025, Syntara announced an open-label Phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary myelofibrosis, post-polycythemia vera (PV) myelofibrosis, or post-essential thrombocythemia (ET) myelofibrosis. The dose-escalation phase will follow a 3+3 design, beginning with a starting dose of 100 mg twice daily for a treatment duration of 4 weeks. Patients will be eligible to participate across multiple dose levels.
* DelveInsight's Polycythemia Vera Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycythemia Vera treatment.
* The leading Polycythemia Vera Companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals and others.
* Promising Polycythemia Vera Pipeline Therapies such as Rusfertide, Givinostat, Hydroxyurea, Bomedemstat, PTG-300, SLN124, Ruxolitinib, P1101 (Ropeginterferon alfa-2b-njft), AOP2014 and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Polycythemia Vera Treatment Drugs [https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polycythemia Vera Emerging Drugs Profile

* Rusfertide: Protagonist Therapeutics

Rusfertide (PTG-300) is an injectable compound that mimics the effect of the natural hormone hepcidin but with greater potency, solubility, and stability. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. The molecular target of the hormone hepcidin is the cellular trans-membrane protein ferroportin, which functions as an export channel for intracellular iron in macrophages, liver hepatocytes, and duodenal enterocytes. By binding to the extracellular domain of ferroportin, hepcidin redistributes iron by reducing the export of iron from inside the enterocytes and macrophages to the systemic circulation. Excessive quantities of iron relative to the lower levels of beta-globin chains in the bone marrow induce ineffective erythropoiesis resulting in anemia. As a hepcidin mimetic, PTG-300 may redistribute iron to the macrophages, reduce iron-induced oxidative stress in the bone marrow, and allow sufficient production of red blood cells. Also, by limiting the release of iron into the blood, PTG-300 may inhibit the damage caused by excessive iron absorption by vital organs such as the liver and heart. Takeda and Protagonist Therapeutics have signed a worldwide license and collaboration agreement for the development and commercialization of rusfertide. Currently, the drug is in the Phase III stage of its development for the treatment of Polycythemia Vera.

* Givinostat: Italfarmaco

Givinostat, developed by Italfarmaco, is a histone deacetylase (HDAC) inhibitor currently being evaluated for the treatment of Polycythemia Vera (PV), a myeloproliferative neoplasm characterized by excessive production of blood cells due to mutations in the JAK2 gene, particularly the JAK2 V617F mutation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Polycythemia Vera.

* Sapablursen: Ionis Pharmaceuticals

Sapablursen, also known as ISIS 702843 or IONIS-TMPRSS6-LRx, is an investigational RNA-targeted medicine developed by Ionis Pharmaceuticals for the treatment of polycythemia vera. It functions by inhibiting the TMPRSS6 protein, which regulates hepcidin, a key hormone involved in iron homeostasis. By increasing hepcidin levels, sapablursen aims to alleviate symptoms associated with PV and reduce the need for frequent phlebotomy treatments. Currently, the drug is in the Phase II stage of development to treat Polycythemia Vera.

* PPMX-T003: Perseus Proteomics

PPMX-T003 is a novel human monoclonal antibody developed by Perseus Proteomics, specifically targeting transferrin receptor 1 (TfR1). Currently, the drug is in the Phase I stage of development to treat Polycythemia Vera.

The Polycythemia Vera Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Polycythemia Vera with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia Vera Treatment.
* Polycythemia Vera Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Polycythemia Vera Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycythemia Vera market

Explore groundbreaking therapies and clinical trials in the Polycythemia Vera Pipeline. Access DelveInsight's detailed report now! @ New Polycythemia Vera Drugs [https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polycythemia Vera Companies

Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals and others.

Polycythemia Vera Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Polycythemia Vera Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Polycythemia Vera Market Drivers and Barriers [https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Polycythemia Vera Pipeline Report

* Coverage- Global
* Polycythemia Vera Companies- Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals and others.
* Polycythemia Vera Pipeline Therapies- Rusfertide, Givinostat, Hydroxyurea, Bomedemstat, PTG-300, SLN124, Ruxolitinib, P1101 (Ropeginterferon alfa-2b-njft), AOP2014 and others.
* Polycythemia Vera Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Polycythemia Vera Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth pipeline report today! @ Polycythemia Vera Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Polycythemia Vera: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Polycythemia Vera- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rusfertide: Protagonist Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Sapablursen: Ionis Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PPMX-T003: Perseus Proteomics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Polycythemia Vera Key Companies
* Polycythemia Vera Key Products
* Polycythemia Vera- Unmet Needs
* Polycythemia Vera- Market Drivers and Barriers
* Polycythemia Vera- Future Perspectives and Conclusion
* Polycythemia Vera Analyst Views
* Polycythemia Vera Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polycythemia-vera-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Polycythemia Vera Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here

News-ID: 4167128 • Views:

More Releases from ABNewswire

TCR Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
TCR Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approv …
DelveInsight's "TCR Therapy Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment
COVID-19 Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
COVID-19 Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals …
DelveInsight's, "COVID-19 Pipeline Insight 2025" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the COVID-19 Pipeline.
Familial Mediterranean Fever Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Familial Mediterranean Fever Pipeline Outlook 2025: Clinical Trial Studies, EMA, …
DelveInsight's "Familial Mediterranean Fever Pipeline Insight 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Familial Mediterranean Fever pipeline landscape. It covers the Familial Mediterranean Fever pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Mediterranean Fever therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the
Alzheimer's Disease Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Alzheimer's Disease Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FD …
DelveInsight's, "Alzheimer's Disease Pipeline Insight 2025" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Alzheimer's Disease

All 5 Releases


More Releases for Polycythemia

Polycythemia Vera Market Massive Growth opportunity Ahead
Polycythemia Vera Market Outlook 2024-2034: Rising Diagnosis Rates and Advancements in Targeted Therapies to Drive Growth Introduction Polycythemia Vera (PV) is a rare chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, and in some cases, white blood cells and platelets. This leads to increased blood viscosity, higher risk of thrombosis, fatigue, headaches, and splenomegaly. PV is primarily associated with mutations in the JAK2 gene, which has shaped the
Polycythemia Vera Pipeline: 10+ Therapies in Development by Pharma Giants Poised …
The Polycythemia Vera (PV) treatment landscape is undergoing significant evolution, driven by leading biopharmaceutical companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, and Perseus Proteomics. With JAK inhibitors like ruxolitinib already established, the focus has now shifted to next-generation therapeutics targeting disease-modifying mechanisms, cytokine signaling pathways, and novel erythropoiesis regulation. These therapies aim to reduce thrombotic risk, alleviate symptom burden, and delay progression to myelofibrosis. DelveInsight's "Polycythemia Vera - Pipeline Insight,
Polycythemia Clinical Trials, Drugs, Key Companies, Polycythemia Treatment Marke …
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight. Polycythemia Overview: Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029). Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.